[go: up one dir, main page]

EE04869B1 - Alfa-lipohape v?i selle derivaadid kasutamiseks migreeni ravis - Google Patents

Alfa-lipohape v?i selle derivaadid kasutamiseks migreeni ravis

Info

Publication number
EE04869B1
EE04869B1 EEP200200098A EEP200200098A EE04869B1 EE 04869 B1 EE04869 B1 EE 04869B1 EE P200200098 A EEP200200098 A EE P200200098A EE P200200098 A EEP200200098 A EE P200200098A EE 04869 B1 EE04869 B1 EE 04869B1
Authority
EE
Estonia
Prior art keywords
migraine
lipoic acid
alpha
treatment
derivatives
Prior art date
Application number
EEP200200098A
Other languages
English (en)
Estonian (et)
Inventor
Schoenen Jean
Engel J�rgen
Wessel Klaus
Peukert Manfred
Lobisch Michael
Borbe Harald
Original Assignee
Viatris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh & Co. Kg filed Critical Viatris Gmbh & Co. Kg
Publication of EE200200098A publication Critical patent/EE200200098A/xx
Publication of EE04869B1 publication Critical patent/EE04869B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200098A 1999-08-30 2000-08-26 Alfa-lipohape v?i selle derivaadid kasutamiseks migreeni ravis EE04869B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PCT/EP2000/008315 WO2001015693A2 (de) 1999-08-30 2000-08-26 BEHANDLUNG DER MIGRÄNE DURCH VERABREICHUNG VON α-LIPONSÄURE ODER DERIVATEN DERSELBEN

Publications (2)

Publication Number Publication Date
EE200200098A EE200200098A (et) 2003-04-15
EE04869B1 true EE04869B1 (et) 2007-08-15

Family

ID=7920152

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200098A EE04869B1 (et) 1999-08-30 2000-08-26 Alfa-lipohape v?i selle derivaadid kasutamiseks migreeni ravis

Country Status (31)

Country Link
US (1) US6251935B1 (is)
EP (1) EP1207878B1 (is)
JP (1) JP4773015B2 (is)
KR (1) KR100624215B1 (is)
CN (1) CN1170535C (is)
AT (1) ATE232725T1 (is)
AU (1) AU781505B2 (is)
BG (1) BG65735B1 (is)
BR (1) BR0013651A (is)
CA (1) CA2382548C (is)
CZ (1) CZ301789B6 (is)
DE (2) DE19941217A1 (is)
DK (1) DK1207878T3 (is)
EE (1) EE04869B1 (is)
ES (1) ES2190985T3 (is)
HR (1) HRP20020168A2 (is)
HU (1) HU229603B1 (is)
IL (2) IL148068A0 (is)
IS (1) IS2214B (is)
MX (1) MXPA02002246A (is)
NO (1) NO328692B1 (is)
NZ (1) NZ517276A (is)
PL (1) PL200928B1 (is)
PT (1) PT1207878E (is)
RS (1) RS50139B (is)
RU (1) RU2232577C2 (is)
SK (1) SK286260B6 (is)
TR (1) TR200200461T2 (is)
UA (1) UA71031C2 (is)
WO (1) WO2001015693A2 (is)
ZA (1) ZA200201637B (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69920260T2 (de) * 1998-11-25 2005-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antioxidationsmittel
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
ES2529060T3 (es) 2008-11-24 2015-02-16 Cedars-Sinai Medical Center Derivados antioxidantes de la camptotecina y nanoesferas antineoplásicas antioxidantes de los mismos
NZ610978A (en) 2009-05-15 2014-11-28 Redx Pharma Ltd Redox drug derivatives
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
PT95826B (pt) * 1989-11-09 1997-11-28 Asta Medica Ag Processo para a preparacao de composicoes farmaceuticas contendo como ingrediente activo acido r-alfa-liponico ou acido s-alfa-liponico
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
EP0604641B1 (en) * 1992-06-30 2002-03-20 SHAPIRO, Howard, K. Use of a combination containing an amine or amine-related derivative of benzoic acid and an amino-polysaccharide in the manufacture of a medicament for the treatment of inflammatory diseases
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
AU728488B2 (en) * 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
WO1999006040A1 (en) * 1997-08-04 1999-02-11 Berry Christopher J Method of treating disease using a tocotrienol and alpha-lipoic acid or derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform
EP1065931A4 (en) * 1998-04-02 2006-10-11 Avicena Group Inc COMPOSITIONS CONTAINING CREATINE COMBINED WITH A SECOND AGENT
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Also Published As

Publication number Publication date
WO2001015693A2 (de) 2001-03-08
WO2001015693A3 (de) 2001-12-20
EE200200098A (et) 2003-04-15
HRP20020168A2 (en) 2003-06-30
CZ301789B6 (cs) 2010-06-23
KR20020060168A (ko) 2002-07-16
HU229603B1 (en) 2014-02-28
IS6284A (is) 2002-02-26
NO20020917D0 (no) 2002-02-25
PL200928B1 (pl) 2009-02-27
PT1207878E (pt) 2003-07-31
IL148068A0 (en) 2002-09-12
BR0013651A (pt) 2002-05-07
JP4773015B2 (ja) 2011-09-14
NO20020917L (no) 2002-02-25
EP1207878A2 (de) 2002-05-29
YU15002A (sh) 2005-03-15
HUP0203025A3 (en) 2004-12-28
JP2003508438A (ja) 2003-03-04
ES2190985T3 (es) 2003-09-01
DE50001301D1 (de) 2003-03-27
BG65735B1 (bg) 2009-09-30
AU7279900A (en) 2001-03-26
UA71031C2 (uk) 2004-11-15
IL148068A (en) 2007-06-03
NO328692B1 (no) 2010-04-26
BG106407A (en) 2002-10-31
CN1371280A (zh) 2002-09-25
IS2214B (is) 2007-03-15
SK2902002A3 (en) 2002-09-10
ZA200201637B (en) 2003-01-29
TR200200461T2 (tr) 2002-08-21
CZ2002655A3 (cs) 2002-07-17
HUP0203025A2 (hu) 2002-12-28
DE19941217A1 (de) 2001-03-15
HK1046637A1 (en) 2003-01-24
SK286260B6 (sk) 2008-06-06
NZ517276A (en) 2004-06-25
AU781505B2 (en) 2005-05-26
DK1207878T3 (da) 2003-06-16
CN1170535C (zh) 2004-10-13
US6251935B1 (en) 2001-06-26
KR100624215B1 (ko) 2006-09-18
CA2382548A1 (en) 2001-03-08
EP1207878B1 (de) 2003-02-19
RU2232577C2 (ru) 2004-07-20
MXPA02002246A (es) 2003-08-20
ATE232725T1 (de) 2003-03-15
RS50139B (sr) 2009-03-25
PL352741A1 (en) 2003-09-08
CA2382548C (en) 2007-07-03

Similar Documents

Publication Publication Date Title
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
MY130441A (en) Solutions containing epinastin
DK1041072T3 (da) Dioxocyclopentylhydroxamsyrer
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
TR200103493T2 (tr) Metaloproteaz önleyicileri
CY1110664T1 (el) Ενδορινικες συνθεσετς
TR199802060T2 (xx) Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
EE04869B1 (et) Alfa-lipohape v?i selle derivaadid kasutamiseks migreeni ravis
WO2001093865A3 (de) Mittel zur therapie von demenzen
EP1219296A4 (en) MEANS TO INHIBIT SEBUM PRODUCTION
EP1226819A4 (en) INHIBITORS FOR THE 20-HETE-PRODUCING ENZYME
DK1232173T3 (da) Nye fusidinsyrederivater
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors
SI1207878T1 (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof

Legal Events

Date Code Title Description
HE1A Change of address
HC1A Change of owner name
HK1A Erratum in gazette
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20170826